New LITOseek biomarkers presented at ESMO have identified upregulation of ribosomal biogenesis and TCR signaling with downregulation of interferon gene clusters in responsive patients
LAUSANNE, SWITZERLAND / ACCESSWIRE / September 9, 2022 / Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions today announced discovery of new Immuno-Transcriptomic signatures for prediction of response to immunotherapy and patient monitoring in metastatic melanoma (MM). The data are presented at the Immuno-Oncology Congress of the European Society of Medical Oncology (ESMO) on September 10th2022 in Paris.
Immune checkpoint inhibitors (ICIs) have become one of the main treatments for patients with metastatic cancer. Although ICIs are highly effective with durable results in some patients, only a minority respond and benefit from the therapy. There is therefore a significant unmet medical need for accurate liquid biopsy precision solutions that can select and monitor patients during ICI therapy.
A